Singapore, 23 November 2017: A NEW breast cancer drug shown to reduce the risk of cancer recurrence will soon be made available in Australia, New Zealand and throughout South-East Asia, following a key license deal between Specialised Therapeutics Asia (ST Asia) and US biopharmaceutical company Puma Biotechnology, Inc. (NASDAQ: PBYI). Under the terms of the
![Arctica Specialised Therapeutics](https://stabiopharma.com/wp-content/uploads/2021/03/stabio-logo.png)